ES2650914T3 - Sales de adición de ácidos de 5alfa-hidroxi-6beta-[2-(1H-imidazol-4-il)etilamino]colestan-3beta-ol - Google Patents

Sales de adición de ácidos de 5alfa-hidroxi-6beta-[2-(1H-imidazol-4-il)etilamino]colestan-3beta-ol Download PDF

Info

Publication number
ES2650914T3
ES2650914T3 ES12775237.6T ES12775237T ES2650914T3 ES 2650914 T3 ES2650914 T3 ES 2650914T3 ES 12775237 T ES12775237 T ES 12775237T ES 2650914 T3 ES2650914 T3 ES 2650914T3
Authority
ES
Spain
Prior art keywords
cholestan
imidazol
ethylamino
hydroxy
6beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12775237.6T
Other languages
English (en)
Inventor
Marc Poirot
Sandrine Poirot
Philippe De Medina
Michaël PAILLASSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Affichem
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Affichem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Affichem filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2650914T3 publication Critical patent/ES2650914T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Una sal de adición de ácidos de 5α-hidroxi-6ß-[2-(1H-imidazol-4-il)etilamino]colestan-3ß-ol formada con un ácido seleccionado del grupo que consiste en ácido 2(S)-hidroxipropanoico, ácido malónico, ácido L-málico, ácido D-tartárico y ácido L-tartárico.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES12775237.6T 2011-10-18 2012-10-17 Sales de adición de ácidos de 5alfa-hidroxi-6beta-[2-(1H-imidazol-4-il)etilamino]colestan-3beta-ol Active ES2650914T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306346 2011-10-18
EP11306346 2011-10-18
PCT/EP2012/070588 WO2013057148A1 (en) 2011-10-18 2012-10-17 ACID ADDITION SALTS OF 5α-HYDROXY-6β-[2-(1H-IMIDAZOL-4-YL)ETHYLAMINO]CHOLESTAN-3β-OL

Publications (1)

Publication Number Publication Date
ES2650914T3 true ES2650914T3 (es) 2018-01-23

Family

ID=47046604

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12775237.6T Active ES2650914T3 (es) 2011-10-18 2012-10-17 Sales de adición de ácidos de 5alfa-hidroxi-6beta-[2-(1H-imidazol-4-il)etilamino]colestan-3beta-ol

Country Status (11)

Country Link
US (1) US20140274984A1 (es)
EP (1) EP2768841B1 (es)
JP (1) JP2014530245A (es)
KR (1) KR20140083014A (es)
CN (1) CN103958541A (es)
AU (1) AU2012324980B2 (es)
CA (1) CA2852622A1 (es)
ES (1) ES2650914T3 (es)
MX (1) MX351610B (es)
RU (1) RU2014119929A (es)
WO (1) WO2013057148A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105611934A (zh) * 2013-09-04 2016-05-25 艾菲彻姆 用于治疗化学敏感性或化学耐药性肿瘤的Dendrogenin A和抗肿瘤剂
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
EP3515453A1 (en) * 2016-09-22 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
AU2020401286A1 (en) 2019-12-13 2022-06-23 Inspirna, Inc. Metal salts and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2838741B1 (fr) * 2002-04-19 2006-01-27 Inst Nat Sante Rech Med Derives de sterols, leur procede de preparation et medicaments les comportant
CN102344480A (zh) * 2011-07-22 2012-02-08 中国人民解放军第三军医大学 树突化胺基甾醇一类物的合成方法

Also Published As

Publication number Publication date
CN103958541A (zh) 2014-07-30
AU2012324980A1 (en) 2014-05-01
WO2013057148A1 (en) 2013-04-25
EP2768841B1 (en) 2017-09-27
RU2014119929A (ru) 2015-11-27
MX2014004744A (es) 2015-05-15
JP2014530245A (ja) 2014-11-17
CA2852622A1 (en) 2013-04-25
US20140274984A1 (en) 2014-09-18
KR20140083014A (ko) 2014-07-03
MX351610B (es) 2017-10-20
AU2012324980B2 (en) 2017-09-21
EP2768841A1 (en) 2014-08-27

Similar Documents

Publication Publication Date Title
ES2650914T3 (es) Sales de adición de ácidos de 5alfa-hidroxi-6beta-[2-(1H-imidazol-4-il)etilamino]colestan-3beta-ol
ES2644844T3 (es) Mecanismo de soporte
ES2602810T3 (es) Composición mejorada
DK2970283T3 (da) Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c
ES2448766T9 (es) Profármacos de dolutegravir
CU20110109A7 (es) Nueva composición a base de ácido gamma-hidroxibutírico
ES2642212T3 (es) Cierre de cremallera
ES2641862T3 (es) Proceso para la elaboración de inhibidores de CCR3
UY34416A (es) ?sales de herbicidas de ácido carboxílico?
JP2012098270A5 (es)
UY34916A (es) "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético"
ES2644847T3 (es) Máquina agrícola
ES2585558T3 (es) Uso de sales de 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio en el tratamiento de una enfermedad cardiovascular
ES2565198T3 (es) Metapneumovirus aviar en oncólisis
ES2427714B1 (es) Nuevos derivados clorados de BODIPY
ES2525528T3 (es) Amicolamicina, método para su producción y su utilización
ES2588766T3 (es) Cartucho de cinta inteligente
ES2478692B1 (es) Formulaciones líquidas de carbocisteína de propiedades mejoradas
ES2526147T3 (es) Ésteres de metronidazol para el tratamiento de la rosácea
RU2008105017A (ru) 2-(4-бромбензилсульфанил)-4,6-диметилникотино-нитрил в качестве антидота 2,4-д на подсолнечнике
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
AR096845A1 (es) Sales de (e)-n-((1s,4s)-4-(dimetilamino)-1,4-difenilciclohexil)-n-metilcinamamida
ES2642712T3 (es) Péptidos de foenixina
ES2443826B1 (es) Modelo animal para identificar compuestos terapéuticamente útiles para el tratamiento de la esclerosis lateral amiotrófica esporádica
ES2644814T3 (es) Montaje de rodillo de alimentación